de Jong M - Search Results

1

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.

Ruigrok EAM, Verkaik NS, de Blois E, de Ridder C, Stuurman D, Roobol SJ, Van Gent DC, de Jong M, Van Weerden WM, Nonnekens J. Ruigrok EAM, et al. Among authors: de jong m, de ridder c, de blois e. Int J Mol Sci. 2022 Jul 21;23(14):8037. doi: 10.3390/ijms23148037. Int J Mol Sci. 2022. PMID: 35887398 Free PMC article.

2

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. De Jong M, et al. Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.

3

Peptide receptor radionuclide therapy.

Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Krenning EP, et al. Among authors: de jong m. Ann N Y Acad Sci. 2004 Apr;1014:234-45. doi: 10.1196/annals.1294.026. Ann N Y Acad Sci. 2004. PMID: 15153440 Review.

4

Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.

Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Breeman WA, et al. Among authors: de jong m, de blois e, de jong mt. Nucl Med Biol. 2004 Aug;31(6):821-4. doi: 10.1016/j.nucmedbio.2004.03.008. Nucl Med Biol. 2004. PMID: 15246375

5

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. de Jong M, et al. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. J Nucl Med. 2005. PMID: 15653647 Free article.

6

Radiolabelling DOTA-peptides with 68Ga.

Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Breeman WA, et al. Among authors: de jong m, de blois e. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85. doi: 10.1007/s00259-004-1702-y. Epub 2005 Jan 18. Eur J Nucl Med Mol Imaging. 2005. PMID: 15655678

7

Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.

de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M. de Visser M, et al. Among authors: de jong m, de ridder cm. J Nucl Med. 2007 Jan;48(1):88-93. J Nucl Med. 2007. PMID: 17204703 Free article.

8

Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.

de Visser M, Verwijnen SM, de Jong M. de Visser M, et al. Among authors: de jong m. Cancer Biother Radiopharm. 2008 Apr;23(2):137-57. doi: 10.1089/cbr.2007.0435. Cancer Biother Radiopharm. 2008. PMID: 18454684 Review.

9

Peptide-receptor radionuclide therapy for endocrine tumors.

van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. van Essen M, et al. Among authors: de jong m. Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Nat Rev Endocrinol. 2009. PMID: 19488074 Review.

10

Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.

Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M. Schroeder RP, et al. Among authors: de jong m, de visser m, de ridder cm. Int J Cancer. 2010 Jun 15;126(12):2826-34. doi: 10.1002/ijc.25000. Int J Cancer. 2010. PMID: 19876914 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,114 results

Search Page